Carvykti provides a treatment for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Cortrophin Gel is indicated for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis and rheumatoid arthritis and excess urinary protein due to nephrotic syndrome.
Kimmtrak is the first TCR therapeutic, the first bispecific T cell engager to treat a solid tumor and the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be approved by the FDA.